MTOR and myelofibrosis: Nevertheless, a recent study reported that another mTOR inhibitor, everolimus, as a single agent, was effective in a phase 1/2 study of patients with myelofibrosis, supporting the notion that deregulated signalling via this pathway is pathogenic in MPNs 37.